AZN

3 Top Healthcare Stocks for a More Aware World

By Faisal Humayun, InvestorPlace Contributor
Even after the novel coronavirus is contained, healthcare stocks will remain in focus. Good time to accumulate stocks with strong growth outlook.

4 Top Stock Trades for Friday: NVDA, LULU, TJX, AZN

By Bret Kenwell, InvestorPlace Contributor
Lululemon Athletica, Nvidia, TJX Companies and AstraZeneca were our top stock trades for Friday. That said, let's look at the charts.

First-Mover Advantage Will Benefit Amarin Stock More Than You Think

By Ian Cooper, InvestorPlace Contributor
Thereā€™s no reason Amarin stock wonā€™t become a big success with Vascepa, especially with access to millions of patients.

Amarin Has the Makings for a Gamechanging Product

By Tom Taulli, InvestorPlace Contributor
Amarin is targeting a huge market, and its main drug -- Vascepa -- is likely to be expanded in its coverage. Hereā€™s a look at whatā€™s ahead for the stock.

New Sanofi CEO 2019: 8 Things to Know About Paul Hudson

By William White, InvestorPlace Writer
There's a new Sanofi CEO preparing to join the company with current CEO Olivier Brandicourt retiring at the end of August.

Is AstraZeneca Stock Worth Buying Before Earnings?

By Nicolas Chahine, InvestorPlace Contributor
AZN stock is great to own, but you should choose your entry points carefully, as AstraZeneca has some short-term risks ahead.

3 Big Stock Charts for Monday: L Brands, Progressive and Packaging Corp. of America

By James Brumley, InvestorPlace Feature Writer
The stock charts of PGR, LB and PKG are going to start the new trading week on the cusp of major moves that have been forming for weeks.

AstraZeneca News: Why AZN Stock Is Sliding Lower Today

By Karl Utermohlen, InvestorPlace Writer
AstraZeneca announced that it has inked a deal with Daiichi Sankyo to improve its oncology branch. AZN stock is down more than 5% on Friday.

AstraZeneca Earnings: AZN Stock Zooms Higher on Q4 Beat

By William White, InvestorPlace Writer
An AstraZeneca earnings beat for the pharmaceutical company's fourth quarter of 2018 has AZN stock heading higher on Thursday.

The 5 Best Dow Jones Stocks to Buy Now

By Aaron Levitt, InvestorPlace Contributor
Don't ignore Dow Jones stocks. They can still power your portfolio. Here are 5 of the best to own in 2019 and beyond!

This Health Care Stock Could Pay Off Big

By Ken Trester
Today I am recommending a bullish trade on AstraZeneca PLC (NYSE:AZN), a biopharmaceutical company focused on the development, discovery and commercialization of prescription medicines for a variety of diseases.

The Outlook for AstraZeneca Is Positive, But It’s Too Early to Pull the Trigger

By Will Healy, InvestorPlace Contributor
AstraZeneca's profits are poised to accelerate, but investors should wait for AZN stock to break out of its range before buying the shares.

Biogen Is the Right Alzheimer’s Stock … At the Wrong Time

By James Brumley, InvestorPlace Feature Writer
BIIB stock jumped on Friday, and for good reason. It's not a buy at these lofty levels, but Biogen has at least earned a spot on your watchlist.

3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

By
Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well. Compare Brokers....

FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

By Karl Utermohlen, InvestorPlace Writer
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.

AstraZeneca plc Stock Slips on Q1 Earnings Miss, Falling Crestor Sales

By William White, InvestorPlace Writer
AstraZeneca plc (AZN) stock was down on Friday following the release of its earnings report for the first quarter of 2018.

3 Emerging Technologies Set to Transform the Pharma World

By
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by....

The Future of Merck & Co., Inc. Stock Is With Keytruda

By James Brumley, InvestorPlace Feature Writer
Merck & Co's cancer drug, Keytruda, saw explosive growth this quarter, making MRK stock a tough name to handicap right now.

AstraZeneca’s (AZN) Solid Earnings Visibility Keep it a Buy

By Portfolio Grader
Portfolio Grader currently ranks AstraZeneca Plc (NYSE:AZN) a Buy. With unique fundamental and quantitative metrics developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. The current Portfolio Grader recommendation on the shares has been in place for the last month.
Load More